Observational studyThoracic cancer2025

Real-World Study of EGFR-TKI Rechallenge With Another TKI After First-Line Osimertinib Discontinuation in Patients With EGFR-Mutated Non-Small Cell Lung Cancer: A Subset Analysis of the Reiwa Study.

Kei Sonehara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.